{
  "url": "https://allermi-site.vercel.app/allermi/allermi-vs-nasonex/",
  "collection": "allermi",
  "slug": "allermi-vs-nasonex",
  "frontmatter": {
    "title": "Allermi vs Nasonex: Compounded Multi-Active vs Lowest-Systemic OTC",
    "description": "Nasonex (<0.1% systemic bioavailability) vs Allermi's compounded multi-active telehealth Rx.",
    "lastReviewed": "2026-04-28T00:00:00.000Z",
    "firstPublished": "2026-04-21T00:00:00.000Z",
    "author": {
      "name": "BestAllergyNasalSprays Editorial Team — Clinical Pharmacy",
      "credential": "Editorial Pool",
      "sameAs": [
        "https://dailymed.nlm.nih.gov/",
        "https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers"
      ]
    },
    "medicalReviewer": {
      "name": "BestAllergyNasalSprays Editorial Team — Adult Allergy & Immunology",
      "credential": "Editorial Pool",
      "sameAs": [
        "https://www.aaaai.org/",
        "https://www.acaai.org/"
      ]
    },
    "primaryKeyword": "allermi vs nasonex",
    "ymylTier": "medium",
    "citations": [],
    "tldr": "Nasonex (OTC mometasone) has the lowest systemic bioavailability of the INCS class (<0.1%), a good pick when minimizing systemic steroid exposure matters. Allermi includes triamcinolone (not mometasone) as its steroid component, alongside other actives. Allermi is 13+ (in most states; 18+ in AK/NM/OR/SC), not prescribed in pregnancy or breastfeeding.",
    "claims": [
      "c-002",
      "c-009",
      "c-010",
      "c-011",
      "c-031",
      "c-032"
    ],
    "draft": false,
    "speakableSelectors": [
      ".answer-box",
      ".claim",
      "h1",
      "h2"
    ],
    "takeaways": [
      {
        "text": "Nasonex systemic bioavailability <0.1%: lowest of the INCS class",
        "tier": "rct"
      },
      {
        "text": "Allermi uses triamcinolone as its steroid, not mometasone",
        "tier": "fda-label"
      },
      {
        "text": "Allermi is 13+ in most states; Nasonex is 2+",
        "tier": "fda-label"
      }
    ],
    "related": [
      {
        "href": "/reviews/nasonex/",
        "label": "Nasonex review",
        "kind": "Product",
        "description": "OTC mometasone, lowest systemic exposure of the class."
      },
      {
        "href": "/reviews/allermi/",
        "label": "Allermi review",
        "kind": "Product",
        "description": "Compounded 4-active Rx (triamcinolone-based)."
      },
      {
        "href": "/allermi/allermi-vs-flonase/",
        "label": "Allermi vs Flonase",
        "kind": "Head-to-head",
        "description": "Same question with fluticasone instead."
      },
      {
        "href": "/allermi/allermi-vs-dymista/",
        "label": "Allermi vs Dymista",
        "kind": "Head-to-head",
        "description": "Compounded vs FDA-approved fixed-dose combo."
      },
      {
        "href": "/compare/flonase-vs-nasonex/",
        "label": "Flonase vs Nasonex",
        "kind": "Head-to-head",
        "description": "OTC steroid alternatives compared."
      },
      {
        "href": "/demographic/elderly/",
        "label": "Nasal sprays for older adults",
        "kind": "Demographic",
        "description": "Why Nasonex's <0.1% systemic matters in polypharmacy."
      },
      {
        "href": "/symptom/congestion/",
        "label": "Best nasal spray for congestion",
        "kind": "Symptom",
        "description": "Where both rank for chronic congestion."
      }
    ],
    "competitor": {
      "id": "nasonex-24hr",
      "name": "Nasonex 24HR"
    }
  },
  "outline": [],
  "evidenceCounts": {
    "metaAnalysis": 0,
    "rct": 0,
    "guideline": 1,
    "fdaLabel": 3,
    "cohort": 0,
    "expert": 2
  },
  "claimIds": [
    "c-002",
    "c-009",
    "c-010",
    "c-011",
    "c-031",
    "c-032"
  ],
  "body": "import Claim from '../../components/Claim.astro';\nimport CitationList from '../../components/CitationList.astro';\n\n<aside class=\"material-connection-disclosure\" role=\"note\" aria-label=\"Material connection disclosure\">**Disclosure (FTC 16 CFR Part 255):** BestAllergyNasalSprays is owned and operated by Allermi, Inc. — the company behind Allermi nasal spray. This is a [material connection](/about/ownership/) between the publisher and a reviewed product. Allermi is ranked under the same public criteria as every other product. Read the full ownership and editorial-policy disclosure [here](/about/ownership/).</aside>\n\n<Claim id=\"c-031\">Mometasone furoate has very low systemic bioavailability (under 1% per the current Nasonex prescribing information), among the lowest of the intranasal corticosteroids</Claim> <Claim id=\"c-032\">Nasonex 24HR Allergy (mometasone furoate 50 mcg/spray) became available OTC in June 2022 and is FDA-labeled for adults and children 2 years of age and older</Claim> <Claim id=\"c-002\">Triamcinolone is an intranasal corticosteroid that reduces nasal inflammation by suppressing the production of inflammatory mediators (cytokines, prostaglandins, leukotrienes) involved in allergic rhinitis. With consistent daily use it gradually controls the inflammation that drives congestion and other nasal symptoms</Claim> <Claim id=\"c-011\">Each active ingredient in Allermi is individually FDA-approved for the treatment of rhinitis. Allermi formulations are prepared by a state-licensed compounding pharmacy under the federal Food, Drug, and Cosmetic Act (section 503A); compounded drug products themselves are not FDA-approved as fixed-dose combinations and are primarily overseen by state pharmacy boards, with FDA conducting surveillance and for-cause inspections</Claim> <Claim id=\"c-010\">Allermi is currently available to eligible patients ages 13 and older across most US states</Claim> <Claim id=\"c-009\">Allermi is not currently prescribed during pregnancy or breastfeeding</Claim>\n\n<CitationList items={[\n { id: \"1\", title: \"DailyMed: Nasonex SPL\", url: \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bb34b5f1-d6c1-42b8-b9a2-1c07a1bb8a7c\", publisher: \"FDA DailyMed\" }\n]} />",
  "claims": [
    {
      "id": "c-002",
      "claim": "Triamcinolone is an intranasal corticosteroid that reduces nasal inflammation by suppressing the production of inflammatory mediators (cytokines, prostaglandins, leukotrienes) involved in allergic rhinitis. With consistent daily use it gradually controls the inflammation that drives congestion and other nasal symptoms",
      "allermi_claim_id": "A2",
      "source_type": "StatPearls",
      "confidence": "high",
      "product_ids": [
        "allermi",
        "nasacort"
      ],
      "ymyl_tier": "medium",
      "physician_signoff": "BestAllergyNasalSprays Team",
      "source_url": "https://www.ncbi.nlm.nih.gov/books/NBK544309/"
    },
    {
      "id": "c-009",
      "claim": "Allermi is not currently prescribed during pregnancy or breastfeeding",
      "allermi_claim_id": "C2",
      "source_type": "allermi-library",
      "confidence": "high",
      "product_ids": [
        "allermi"
      ],
      "ymyl_tier": "hard",
      "physician_signoff": "BestAllergyNasalSprays Team",
      "source_url": "https://www.allermi.com/pages/eligibility"
    },
    {
      "id": "c-010",
      "claim": "Allermi is currently available to eligible patients ages 13 and older across most US states",
      "allermi_claim_id": "C1",
      "source_type": "allermi-library",
      "confidence": "high",
      "product_ids": [
        "allermi"
      ],
      "ymyl_tier": "soft",
      "source_url": "https://www.allermi.com/pages/eligibility"
    },
    {
      "id": "c-011",
      "claim": "Each active ingredient in Allermi is individually FDA-approved for the treatment of rhinitis. Allermi formulations are prepared by a state-licensed compounding pharmacy under the federal Food, Drug, and Cosmetic Act (section 503A); compounded drug products themselves are not FDA-approved as fixed-dose combinations and are primarily overseen by state pharmacy boards, with FDA conducting surveillance and for-cause inspections",
      "allermi_claim_id": "B3",
      "source_url": "https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers",
      "source_type": "FDA",
      "confidence": "high",
      "product_ids": [
        "allermi"
      ],
      "ymyl_tier": "hard",
      "physician_signoff": "BestAllergyNasalSprays Team (legal-reviewed)"
    },
    {
      "id": "c-031",
      "claim": "Mometasone furoate has very low systemic bioavailability (under 1% per the current Nasonex prescribing information), among the lowest of the intranasal corticosteroids",
      "source_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020762s056lbl.pdf",
      "source_type": "FDA-label",
      "confidence": "high",
      "product_ids": [
        "nasonex"
      ],
      "ymyl_tier": "medium"
    },
    {
      "id": "c-032",
      "claim": "Nasonex 24HR Allergy (mometasone furoate 50 mcg/spray) became available OTC in June 2022 and is FDA-labeled for adults and children 2 years of age and older",
      "source_url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=30507dfb-c5a4-4e27-e063-6294a90aa87e",
      "source_type": "FDA-label",
      "confidence": "high",
      "product_ids": [
        "nasonex"
      ],
      "ymyl_tier": "soft"
    }
  ]
}